Carmichael Hill & Associates’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Hold
0
-$37.9K 782
2023
Q4
Hold
0
387
2023
Q3
Hold
0
374
2023
Q2
Hold
0
378
2023
Q1
Hold
0
367
2022
Q4
Hold
0
383
2022
Q3
Hold
0
378
2022
Q2
Sell
-600
Closed -$33K 377
2022
Q1
$37K Buy
+600
New +$39.5K 0.02% 414

Other funds holding FLGT

Carmichael Hill & Associates's FLGT Position: Q1 2022 in Review

Carmichael Hill & Associates sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 500 shares — an estimated $32.9K sold.

Carmichael Hill & Associates first reported a position in FLGT in Q1 2021 and held it in 4 quarters. The position peaked at $50K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Carmichael Hill & Associates reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Carmichael Hill & Associates sold 500 Fulgent Genetics shares in Q1 2022, an estimated $32.9K.
  • Carmichael Hill & Associates first reported a position in Fulgent Genetics in Q1 2021 and held it in 4 quarters.
  • Carmichael Hill & Associates's Fulgent Genetics position peaked at $50K in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Carmichael Hill & Associates's 13F filing for Q1 2022, filed 16 May 2022.